ADAPTIMMUNE

adaptimmune-logo

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

#SimilarOrganizations #People #Financial #Event #Website #More

ADAPTIMMUNE

Social Links:

Industry:
Biopharma Biotechnology Health Care Medical

Founded:
2008-01-01

Address:
Oxton, York, United Kingdom

Country:
United Kingdom

Website Url:
http://www.adaptimmune.com

Total Employee:
501+

Status:
Active

Contact:
+1 (215) 825 9260

Email Addresses:
[email protected]

Total Funding:
499.5 M USD

Technology used in webpage:
Domain Not Resolving IPv6 ReCAPTCHA Nginx ReCAPTCHA V2 DoubleClick.Net Microsoft Google Adsense Mobile Optimized New Relic


Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

agenus-logo

Agenus

Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.

cel-sci-logo

CEL-SCI

CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.

cytokinetics-logo

Cytokinetics

Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.

healx-logo

Healx

Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.

kuros-biosciences-logo

Kuros Biosciences

Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.

lineage-cell-therapeutics-logo

Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.

soligenix-logo

Soligenix

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.

theravectys-logo

Theravectys

Theravectys develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.


Current Advisors List

elliott-sigal_image

Elliott Sigal Board Member @ Adaptimmune
Board_member
2014-09-01

garry-menzel_image

Garry Menzel Board Director @ Adaptimmune
Board_member

Current Employees Featured

not_available_image

Gavin Wood
Gavin Wood Chief Financial Officer @ Adaptimmune
Chief Financial Officer
2020-04-01

not_available_image

William (Bill) Bertrand
William (Bill) Bertrand Chief Operating Officer @ Adaptimmune
Chief Operating Officer

ian-laing_image

Ian Laing
Ian Laing Founder & Non-Executive Director @ Adaptimmune
Founder & Non-Executive Director
2008-12-01

helen-tayton-martin_image

Helen Tayton-Martin
Helen Tayton-Martin Chief Business Officer @ Adaptimmune
Chief Business Officer
2008-07-01

not_available_image

Adrian (Ad) Rawcliffe
Adrian (Ad) Rawcliffe Chief Executive Officer @ Adaptimmune
Chief Executive Officer

cintia-piccina_image

Cintia Piccina
Cintia Piccina Chief Commercial Officer @ Adaptimmune
Chief Commercial Officer
2024-01-01

not_available_image

Dennis Williams
Dennis Williams TitleSr. Vice President, Late Stage Development @ Adaptimmune
TitleSr. Vice President, Late Stage Development
2019-12-01

not_available_image

John Lunger
John Lunger Chief Patient Supply Officer @ Adaptimmune
Chief Patient Supply Officer

james-noble_image

James Noble
James Noble Founder & CEO @ Adaptimmune
Founder & CEO
2008-07-01

not_available_image

Elliot Norry
Elliot Norry Senior Vice President & Chief Medical Officer @ Adaptimmune
Senior Vice President & Chief Medical Officer

Founder


ian-laing_image

Ian Laing

james-noble_image

James Noble

Stock Details


Company's stock symbol is NASDAQ:ADAP

Acquisitions List

Date Company Article Price
2023-03-06 TCR2 TCR2 acquired by Adaptimmune N/A

Investors List

herculescapital_image

Hercules Capital

Hercules Capital investment in Post-IPO Debt - Adaptimmune

genentech_image

Genentech

Genentech investment in Post-IPO Equity - Adaptimmune

eight-roads-ventures_image

Eight Roads Ventures

Eight Roads Ventures investment in Venture Round - Adaptimmune

merlin-nexus_image

Merlin Nexus

Merlin Nexus investment in Series A - Adaptimmune

f-prime-capital-partners_image

F-Prime Capital

F-Prime Capital investment in Series A - Adaptimmune

wellington-management_image

Wellington Management

Wellington Management investment in Series A - Adaptimmune

ridgeback-capital_image

Ridgeback Capital

Ridgeback Capital investment in Series A - Adaptimmune

university-of-oxford_image

University of Oxford

University of Oxford investment in Series A - Adaptimmune

foresite-capital_image

Foresite Capital

Foresite Capital investment in Series A - Adaptimmune

novo-a-s_image

Novo Holdings

Novo Holdings investment in Series A - Adaptimmune

Official Site Inspections

http://www.adaptimmune.com Semrush global rank: 1.47 M Semrush visits lastest month: 16.99 K

  • Host name: ec2-174-129-30-187.compute-1.amazonaws.com
  • IP address: 174.129.30.187
  • Location: Ashburn United States
  • Latitude: 39.0481
  • Longitude: -77.4728
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20149

Loading ...

More informations about "Adaptimmune"

Adaptimmune - Wikipedia

Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University โ€ฆSee details»

Leadership Team :: Adaptimmune (ADAP)

In this role, she built the Allogeneic Research organization from the ground up and took the concept of iPSC-derived allogeneic T-cell therapies from an idea into the potential for an allogeneic candidate in the clinic. Prior to her SVP โ€ฆSee details»

Our Company :: Adaptimmune (ADAP)

Adaptimmune embraces this personalized approach from discovery through delivery with fully integrated capabilities including research, global clinical development, translational sciences, commercialization, and manufacturing.See details»

Adaptimmune - Crunchbase Company Profile & Funding

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor โ€ฆSee details»

Adaptimmune - The Org

Adaptimmune is a multinational, clinical-stage #biotech company focused on developing novel immunotherapies that can potentially transform cancer treatment Industries Biotechnology , EducationSee details»

Adaptimmune - Company Profile - Tracxn

Dec 7, 2024 What are the most recent funding rounds of Adaptimmune? Its latest funding round was a Series A round on Sep 24, 2014 for $104M. 12 investors participated in its latest round, โ€ฆSee details»

Adaptimmune Information - RocketReach

Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities โ€ฆSee details»

Adaptimmune - Funding, Financials, Valuation & Investors

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. Search Crunchbase. Start Free Trial . Chrome Extension. ... Which types โ€ฆSee details»

Member profile: Adaptimmune Ltd | BIA - bioindustry.org

Adaptimmune, a leader in cell therapy, is a late-stage biopharmaceutical company, with a pipeline of therapies in clinical trials in 10 solid tumors. About Adaptimmune Ltd Adaptimmune, a โ€ฆSee details»

Company Information - Adaptimmune (ADAP)

Adaptimmune is a leader in TCR T-cell therapy, focused on designing and delivering novel cancer immunotherapy products. We utilize the bodyโ€™s own machinery โ€“ the T-cell โ€“ to target and destroy cancer. We believe our โ€ฆSee details»

Adaptimmune Company Profile: Overview and Full News Analysis

Adaptimmune is reducing its headcount by 33% and targeting approximately $300 million in aggregate cost savings over the next four years . As part of this restructuring, the Company โ€ฆSee details»

Adaptimmune Company Profile - Office Locations, Competitors

Oct 29, 2024 Adaptimmune has 4 employees across 4 locations and $60.28 m in annual revenue in FY 2023. See insights on Adaptimmune including office locations, competitors, โ€ฆSee details»

US FDA approves Adaptimmune's therapy for rare type of cancer

Aug 2, 2024 The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind treatment for a rare type of cancer in the soft tissues that most โ€ฆSee details»

Investor Relations :: Adaptimmune (ADAP)

Nov 18, 2024 Adaptimmune is a leader in TCR T-cell therapy, focused on designing and delivering novel cancer immunotherapy products. We utilize the bodyโ€™s own machinery โ€“ the T โ€ฆSee details»

Adaptimmune to File for Lete-Cel FDA Approval Following Cuts โ€ฆ

2 days ago Adaptimmune estimates that 400 new sarcoma patients per year are currently eligible for Tecelra, and that closer to 1,000 new sarcoma patients per year would be eligible โ€ฆSee details»

Adaptimmune Assist

AdaptimmuneAssist includes: โ€ Connection with a Treatment Navigator โ€ Travel and financial support programs for eligible patients โ€ Access to the AdaptimmuneAssist Order PortalSee details»

Our Leaders :: Adaptimmune (ADAP)

Prior to her SVP role, Dr. Brewer held a series of senior managerial roles within Adaptimmuneโ€™s research organization. Her experience in immunotherapy and cell therapy at Adaptimmune โ€ฆSee details»

AGC Biologics to Support Adaptimmuneโ€™s Solid Tumor Cell Therapy

17 hours ago AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), has announced a development and manufacturing โ€ฆSee details»

Corporate Presentations :: Adaptimmune (ADAP)

4 days ago Latest Corporate Deck. Jan 13, 2025. Adaptimmune Corporate Deck January 2025See details»

Adaptimmune Announces U.S. FDA Breakthrough Therapy โ€ฆ

3 days ago Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine โ€ฆSee details»

linkstock.net © 2022. All rights reserved